Psyence Biomedical Ltd. PBM
5.56
(0.30)
(5.12%)
as of 25 Sep
- Market cap
- $22.4M
- P/E
- 0.2×
Follow PBM
| Mar '26 | Mar '25 | Mar '24 | Dec '23 | Jan '22 | Jan '21 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
14.62 | 11.04 | 0.09 | 0.09 | 0.08 | 14.17 | — |
Net Debt/EBITDA |
1.20 | 1.69 | 0.28 | 0.28 | 0.10 | 1.94 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.17 | (3.69) | 0.06 | 0.00 | (0.06) | (0.10) | — |
Capex/Depreciation |
(0.04) | (2.30) | (28.50) | — | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (58.62%) | (47.61%) | 149.52% | (54.66%) | 3.33% | 0.00% | — | |
| (55.75%) | 23.95% | (4,518.56%) | (39.34%) | 3.11% | 6.42% | — | |
ROIC |
(41.24%) | (415.57%) | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(81.67%) | 16.93% | 466.25% | 466.25% | (61.34%) | 909.94% | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | — | — | — |
Free Cash Flow per Share |
(14.74) | (121.17) | (1,735.94) | 0.00 | (0.02) | (0.03) | — |
Cash per Share |
13.57 | 199.71 | 448.71 | 0.09 | 0.00 | 0.02 | — |
Shareholders Equity per Share |
30.68 | 217.54 | (6,454.41) | (1.32) | 7.49 | 7.24 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
30.68 | 217.54 | (6,454.41) | (1.32) | 7.49 | 7.24 | — |
Free Cash Flow |
(8.14) | (3.74) | (2.95) | — | (0.52) | (0.84) | — |
Working Capital |
8.49 | 5.97 | (10.98) | (10.98) | (13.07) | 0.90 | — |
Capital Expenditures |
0.00 | (0.01) | (0.01) | — | — | — | — |
Net Current Asset Value |
8.49 | 5.97 | (10.98) | (10.98) | (13.07) | (18.61) | — |
| Other line items | |||||||
Quick Ratio |
12.60 | 10.61 | 0.07 | 0.07 | 0.07 | 9.44 | — |
Depreciation/Fixed assets |
0.87 | 0.39 | 0.04 | 0.00 | — | — | — |
Cash ROIC |
(33.35%) | (29.05%) | 28.90% | 0.05% | (0.21%) | (0.35%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(14.74) | (120.85) | (1,732.59) | 0.00 | (0.02) | (0.03) | — |
Capex per Share |
0.00 | (0.32) | (3.35) | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
0.25 | 0.09 | 0.04 | 0.44 | — | — | — |
Average Payables |
0.40 | 0.57 | — | — | — | — | — |
Average Assets |
12.44 | 4.22 | 1.13 | 130.03 | 257.58 | 128.11 | — |
Average Common Equity |
11.83 | (2.13) | (34.22) | 93.60 | 240.65 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | — | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates